Hypothyroidism/subclinical hypothyroidism and metabolic dysfunction-associated steatotic liver disease: advances in mechanism and treatment
Abstract Hypothyroidism is a risk factor for metabolic dysfunction-associated steatotic liver disease (MASLD) but it is not clear whether subclinical hypothyroidism (SCH) increases the risk of MASLD and whether SCH patients with MASLD require treatment. In this study, we reviewed articles published...
| 主要な著者: | , , , |
|---|---|
| フォーマット: | 論文 |
| 言語: | English |
| 出版事項: |
BMC
2025-02-01
|
| シリーズ: | Lipids in Health and Disease |
| 主題: | |
| オンライン･アクセス: | https://doi.org/10.1186/s12944-025-02474-0 |
| _version_ | 1826798948309794816 |
|---|---|
| author | Sicheng Pu Binbin Zhao Yuxuan Jiang Xuejiao Cui |
| author_facet | Sicheng Pu Binbin Zhao Yuxuan Jiang Xuejiao Cui |
| author_sort | Sicheng Pu |
| collection | DOAJ |
| description | Abstract Hypothyroidism is a risk factor for metabolic dysfunction-associated steatotic liver disease (MASLD) but it is not clear whether subclinical hypothyroidism (SCH) increases the risk of MASLD and whether SCH patients with MASLD require treatment. In this study, we reviewed articles published in PubMed from 2013 to 2024 with SCH/hypothyroidism and MASLD as keywords. According to the studies retrieved, SCH increases the likelihood of developing MASLD. Thyroid hormones influence energy metabolism and storage in adipose tissues, as well as fatty acid and cholesterol metabolism and transport in the liver. L-T4 replacement therapy reduces the prevalence of MASLD, especially in patients with severe SCH or mild SCH with dyslipidemia. Recent studies showed that thyroid hormone analogues and thyroid hormone β receptor agonists obtained positive results in the treatment of MASLD in animal models and clinical trials, and Resmetirom has been approved by the US. Food and Drug Administration (FDA) under the name Rezdiffra for use in conjunction with dietary and exercise regimens for managing non-cirrhotic NASH in adults with moderate to advanced fibrosis. |
| first_indexed | 2025-03-14T08:59:05Z |
| format | Article |
| id | doaj.art-a6e92d5207c941ef85cd4de7f7b51cf8 |
| institution | Directory Open Access Journal |
| issn | 1476-511X |
| language | English |
| last_indexed | 2025-03-14T08:59:05Z |
| publishDate | 2025-02-01 |
| publisher | BMC |
| record_format | Article |
| series | Lipids in Health and Disease |
| spelling | doaj.art-a6e92d5207c941ef85cd4de7f7b51cf82025-03-02T12:44:00ZengBMCLipids in Health and Disease1476-511X2025-02-0124111610.1186/s12944-025-02474-0Hypothyroidism/subclinical hypothyroidism and metabolic dysfunction-associated steatotic liver disease: advances in mechanism and treatmentSicheng Pu0Binbin Zhao1Yuxuan Jiang2Xuejiao Cui3China Medical UniversityChina Medical UniversityChina Medical UniversityDepartment of Endocrinology, Shengjing Hospital of China Medical UniversityAbstract Hypothyroidism is a risk factor for metabolic dysfunction-associated steatotic liver disease (MASLD) but it is not clear whether subclinical hypothyroidism (SCH) increases the risk of MASLD and whether SCH patients with MASLD require treatment. In this study, we reviewed articles published in PubMed from 2013 to 2024 with SCH/hypothyroidism and MASLD as keywords. According to the studies retrieved, SCH increases the likelihood of developing MASLD. Thyroid hormones influence energy metabolism and storage in adipose tissues, as well as fatty acid and cholesterol metabolism and transport in the liver. L-T4 replacement therapy reduces the prevalence of MASLD, especially in patients with severe SCH or mild SCH with dyslipidemia. Recent studies showed that thyroid hormone analogues and thyroid hormone β receptor agonists obtained positive results in the treatment of MASLD in animal models and clinical trials, and Resmetirom has been approved by the US. Food and Drug Administration (FDA) under the name Rezdiffra for use in conjunction with dietary and exercise regimens for managing non-cirrhotic NASH in adults with moderate to advanced fibrosis.https://doi.org/10.1186/s12944-025-02474-0HypothyroidismSubclinical hypothyroidismNon-alcoholic fatty liver diseaseMetabolic dysfunction-associated steatotic liver diseaseMolecular rolesThyroid-related medication |
| spellingShingle | Sicheng Pu Binbin Zhao Yuxuan Jiang Xuejiao Cui Hypothyroidism/subclinical hypothyroidism and metabolic dysfunction-associated steatotic liver disease: advances in mechanism and treatment Lipids in Health and Disease Hypothyroidism Subclinical hypothyroidism Non-alcoholic fatty liver disease Metabolic dysfunction-associated steatotic liver disease Molecular roles Thyroid-related medication |
| title | Hypothyroidism/subclinical hypothyroidism and metabolic dysfunction-associated steatotic liver disease: advances in mechanism and treatment |
| title_full | Hypothyroidism/subclinical hypothyroidism and metabolic dysfunction-associated steatotic liver disease: advances in mechanism and treatment |
| title_fullStr | Hypothyroidism/subclinical hypothyroidism and metabolic dysfunction-associated steatotic liver disease: advances in mechanism and treatment |
| title_full_unstemmed | Hypothyroidism/subclinical hypothyroidism and metabolic dysfunction-associated steatotic liver disease: advances in mechanism and treatment |
| title_short | Hypothyroidism/subclinical hypothyroidism and metabolic dysfunction-associated steatotic liver disease: advances in mechanism and treatment |
| title_sort | hypothyroidism subclinical hypothyroidism and metabolic dysfunction associated steatotic liver disease advances in mechanism and treatment |
| topic | Hypothyroidism Subclinical hypothyroidism Non-alcoholic fatty liver disease Metabolic dysfunction-associated steatotic liver disease Molecular roles Thyroid-related medication |
| url | https://doi.org/10.1186/s12944-025-02474-0 |
| work_keys_str_mv | AT sichengpu hypothyroidismsubclinicalhypothyroidismandmetabolicdysfunctionassociatedsteatoticliverdiseaseadvancesinmechanismandtreatment AT binbinzhao hypothyroidismsubclinicalhypothyroidismandmetabolicdysfunctionassociatedsteatoticliverdiseaseadvancesinmechanismandtreatment AT yuxuanjiang hypothyroidismsubclinicalhypothyroidismandmetabolicdysfunctionassociatedsteatoticliverdiseaseadvancesinmechanismandtreatment AT xuejiaocui hypothyroidismsubclinicalhypothyroidismandmetabolicdysfunctionassociatedsteatoticliverdiseaseadvancesinmechanismandtreatment |